ARTICLE | Translation in Brief

Translational tidbits

November 13, 2014 8:00 AM UTC

With a few pharmas entering the search for tankyrase inhibitors for cancer, Merck KGaA is hedging its bets by joining forces with The Institute of Cancer Research and the Wellcome Trust to accelerate development of selective inhibitors of the enzymes.

The two tankyrases-tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS) and TNKS2-are members of the poly(ADP-ribose) polymerase (PARP) family of enzymes that transfer ADP-ribose groups to a range of cellular proteins and are upregulated in a variety of cancers...